14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: A prospective study in 112 patients

A. W. Lemstra; M. T. Van Meegen; J. P. Vreyling; P. H.S. Meijerink; G. H. Jansen; S. Bulk; F. Baas; W. A. Van Gool

doi:https://doi.org/10.1212/WNL.55.4.514

14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: A prospective study in 112 patients

A. W. Lemstra, M. T. Van Meegen, J. P. Vreyling, P. H.S. Meijerink, G. H. Jansen, S. Bulk, F. Baas, W. A. Van Gool

Other Departments

Research output: Contribution to journal › Article › Academic › peer-review

115 Citations (Scopus)

Abstract

Objective: To study the sensitivity and specificity of 14-3-3 testing in a prospective series of patients suspected of having Creutzfeldt-Jakob disease (CJD). Background: The 14-3-3 protein immunoassay on CSF has favorable test characteristics as a premortem diagnostic tool in CJD. However, the 14-3-3 protein is a normal cellular protein expressed in various tissues, and its presence in CSF reflects extensive destruction of brain tissue as in CJD, but also in ischemic stroke and meningoencephalitis. Methods: 14-3-3 was tested in the CSF of a prospective series of 110 consecutive patients suspected of having CJD. Results: The sensitivity was 97% and the specificity was 87% in this series. False-positive results were mainly caused by stroke and meningoencephalitis. Conclusion: The 14-3-3 protein is a highly sensitive and specific marker for CJD when used in the appropriate clinical context.

Original language	English
Pages (from-to)	514-516
Number of pages	3
Journal	Neurology
Volume	55
Issue number	4
DOIs	https://doi.org/10.1212/WNL.55.4.514
Publication status	Published - 1 Jan 2000

Access to Document

https://doi.org/10.1212/WNL.55.4.514

Cite this

@article{cb66d1e4911648c19fbd4f6962ff0032,

title = "14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: A prospective study in 112 patients",

abstract = "Objective: To study the sensitivity and specificity of 14-3-3 testing in a prospective series of patients suspected of having Creutzfeldt-Jakob disease (CJD). Background: The 14-3-3 protein immunoassay on CSF has favorable test characteristics as a premortem diagnostic tool in CJD. However, the 14-3-3 protein is a normal cellular protein expressed in various tissues, and its presence in CSF reflects extensive destruction of brain tissue as in CJD, but also in ischemic stroke and meningoencephalitis. Methods: 14-3-3 was tested in the CSF of a prospective series of 110 consecutive patients suspected of having CJD. Results: The sensitivity was 97% and the specificity was 87% in this series. False-positive results were mainly caused by stroke and meningoencephalitis. Conclusion: The 14-3-3 protein is a highly sensitive and specific marker for CJD when used in the appropriate clinical context.",

author = "Lemstra, {A. W.} and {Van Meegen}, {M. T.} and Vreyling, {J. P.} and Meijerink, {P. H.S.} and Jansen, {G. H.} and S. Bulk and F. Baas and {Van Gool}, {W. A.}",

year = "2000",

month = jan,

day = "1",

doi = "https://doi.org/10.1212/WNL.55.4.514",

language = "English",

volume = "55",

pages = "514--516",

journal = "Neurology",

issn = "0028-3878",

publisher = "American Academy of Neurology",

number = "4",

}

TY - JOUR

T1 - 14-3-3 testing in diagnosing Creutzfeldt-Jakob disease

T2 - A prospective study in 112 patients

AU - Lemstra, A. W.

AU - Van Meegen, M. T.

AU - Vreyling, J. P.

AU - Meijerink, P. H.S.

AU - Jansen, G. H.

AU - Bulk, S.

AU - Baas, F.

AU - Van Gool, W. A.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Objective: To study the sensitivity and specificity of 14-3-3 testing in a prospective series of patients suspected of having Creutzfeldt-Jakob disease (CJD). Background: The 14-3-3 protein immunoassay on CSF has favorable test characteristics as a premortem diagnostic tool in CJD. However, the 14-3-3 protein is a normal cellular protein expressed in various tissues, and its presence in CSF reflects extensive destruction of brain tissue as in CJD, but also in ischemic stroke and meningoencephalitis. Methods: 14-3-3 was tested in the CSF of a prospective series of 110 consecutive patients suspected of having CJD. Results: The sensitivity was 97% and the specificity was 87% in this series. False-positive results were mainly caused by stroke and meningoencephalitis. Conclusion: The 14-3-3 protein is a highly sensitive and specific marker for CJD when used in the appropriate clinical context.

AB - Objective: To study the sensitivity and specificity of 14-3-3 testing in a prospective series of patients suspected of having Creutzfeldt-Jakob disease (CJD). Background: The 14-3-3 protein immunoassay on CSF has favorable test characteristics as a premortem diagnostic tool in CJD. However, the 14-3-3 protein is a normal cellular protein expressed in various tissues, and its presence in CSF reflects extensive destruction of brain tissue as in CJD, but also in ischemic stroke and meningoencephalitis. Methods: 14-3-3 was tested in the CSF of a prospective series of 110 consecutive patients suspected of having CJD. Results: The sensitivity was 97% and the specificity was 87% in this series. False-positive results were mainly caused by stroke and meningoencephalitis. Conclusion: The 14-3-3 protein is a highly sensitive and specific marker for CJD when used in the appropriate clinical context.

UR - http://www.scopus.com/inward/record.url?scp=0033837134&partnerID=8YFLogxK

U2 - https://doi.org/10.1212/WNL.55.4.514

DO - https://doi.org/10.1212/WNL.55.4.514

M3 - Article

C2 - 10953182

SN - 0028-3878

VL - 55

SP - 514

EP - 516

JO - Neurology

JF - Neurology

IS - 4

ER -

14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: A prospective study in 112 patients

Abstract

Access to Document

Other files and links

Cite this